OPKO Health, Inc. (NASDAQ:OPK) Receives Consensus Rating of “Hold” from Brokerages

OPKO Health, Inc. (NASDAQ:OPK) has been assigned a consensus rating of “Hold” from the six research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $1.55.

Several brokerages have recently weighed in on OPK. Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Weiss Ratings raised shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Finally, Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 29th.

OPKO Health Price Performance

Shares of NASDAQ OPK opened at $1.49 on Thursday. The firm’s 50-day moving average price is $1.28 and its 200-day moving average price is $1.26. OPKO Health has a 1-year low of $0.98 and a 1-year high of $1.60. The firm has a market capitalization of $1.13 billion, a P/E ratio of -5.52 and a beta of 1.50. The company has a current ratio of 3.61, a quick ratio of 3.17 and a debt-to-equity ratio of 0.28.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. The firm had revenue of $124.20 million for the quarter, compared to analyst estimates of $130.51 million. During the same quarter in the prior year, the business earned ($0.10) earnings per share. The business’s quarterly revenue was down 17.1% compared to the same quarter last year. Equities research analysts anticipate that OPKO Health will post -0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently made changes to their positions in OPK. Goldman Sachs Group Inc. increased its position in shares of OPKO Health by 150.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock worth $7,544,000 after acquiring an additional 3,600,378 shares in the last quarter. Millennium Management LLC increased its position in shares of OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after acquiring an additional 1,798,385 shares in the last quarter. AQR Capital Management LLC increased its position in shares of OPKO Health by 466.7% during the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock worth $2,671,000 after acquiring an additional 1,324,988 shares in the last quarter. OP Asset Management Ltd bought a new stake in shares of OPKO Health during the first quarter worth about $1,257,000. Finally, HRT Financial LP bought a new stake in shares of OPKO Health during the fourth quarter worth about $851,000. 64.63% of the stock is owned by institutional investors.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.